This page shows the latest Oxford BioMedica news and features for those working in and with pharma, biotech and healthcare.
Cell and gene therapy specialist Oxford Biomedica has been given a £53.5m infusion of cash from Novo Holdings in exchange for a 10% stake in the company. ... John Dawson. “We are delighted that Novo Holdings has become a shareholder in Oxford Biomedica
Will develop in silico models and novel algorithms. Oxford Biomedica has entered into a two-year research and development partnership with Microsoft to change the way gene therapies are delivered and ... Oxford Biomedica’s lentiviral vectors platform,
Roche, Celgene, IQVIA and Oxford Biomedica. Her role also includes looking at ways in which the sector can make the most of Brexit - although the UK's pharma and biotech sector
licensed rights to a gene therapy for Parkinson’s disease (PD) from UK biotech Oxford BioMedica for $30m upfront.
£19m commitment from Oxford BioMedica to expand manufacturing facilities.
Also receiving funding is Oxford BioMedica, one of the UK’s leading manufacturers of cell and gene therapies, best know for supplying the lentiviral vector used in Novartis’ CAR-T therapy ... Oxford Biomedica will look to dramatically reduce the
More from news
Approximately 3 fully matching, plus 36 partially matching documents found.
Another example which shows the versatility of new CAR-T innovation is provided by Oxford Biomedica, a gene and cell therapy company specialising in the development of gene-based medicines. ... Collaborating with pharma companies, Oxford Biomedica uses
95. Oxford BioMedica/Novartis. Expansion of collaboration. Lentiviral vectors expressing CTL019 CAR-T therapy for leukaemia.
First closed in May 2013, Novartis has expanded its collaboration with Oxford BioMedica. ... This is focused on the manufacture and supply, using Oxford's LentiVector gene delivery technology, to express Novartis' chimeric antigen receptor T cell [CAR-T]
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Prior to this, he was non-executive director and then chairman of Oxford BioMedica, a gene-based biopharmaceutical company.
Prior to joining Ora, Dr Chandler served as principal of Sci-pHecta Consulting from 2013 and has also held leadership roles at Bausch Lamb, Ista Pharmaceuticals, NightStaRx BioPharmaceuticals and Oxford BioMedica
James Christie joins from Oxford BioMedica. The Association of the British Pharmaceutical Industry (ABPI) has named James Christie as its first project director with responsibility for manufacturing. ... Prior to joining ABPI, Christie worked for Oxford
John Dawson, CEO of Oxford BioMedica, said: “His insight and guidance as a Non-Executive Board member have been invaluable and his extensive experience in the strategic clinical development of innovative ... therapies will be important to Oxford
The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.
More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...